Comparing ceftolozane/tazobactam versus piperacillin/tazobactam as empiric therapy for complicated urinary tract infection in Taiwan: A cost-utility model focusing on gram-negative bacteria.

CONCLUSIONS: Our results suggest that empiric use of ceftolozane/tazobactam for the treatment of cUTI could be a cost-effective choice in Taiwan. PMID: 31029529 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/31029529?dopt=Abstract

Source: Journal of Microbiology, Immunology, and Infection - April 15, 2019 Category: Microbiology Authors: Chen GJ, Pan SC, Foo J, Morel C, Chen WT, Wang JT Tags: J Microbiol Immunol Infect Source Type: research